Trial Profile

A Retrospective Study for Evaluation of Real-world Efficacy and Safety of T-DM1 in HER2-positive Locally-advanced Unresectable or Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jun 2022 Results from NCT04192734 and NCT04202328; establishing a data collection framework of EMR-based RWD, evaluate the effectiveness and safety of ramucirumab plus paclitaxel and trastuzumab-emtansine, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
20 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com